Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

References

• Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975–4981
   PubMed Web of Science ®Google Scholar
• Campo E, Raffeld M, Jaffe E S. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127
   PubMed Web of Science ®Google Scholar
• Fisher R I, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, de V S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Muzzy J, Gregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
   PubMed Web of Science ®Google Scholar
• Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, Kammer W, et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007; 21: 84–92
   PubMed Web of Science ®Google Scholar
• Rizzatti E G, Falcao R P, Panepucci R A, Proto-Siqueira R, nselmo-Lima W T, Okamoto O K, et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005; 130: 516–526
   PubMed Web of Science ®Google Scholar
• Rudelius M, Pittaluga S, Nishizuka S, Pham T H, Fend F, Jaffe E S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108: 1668–1676
   PubMed Web of Science ®Google Scholar
• Pham L V, Tamayo A T, Yoshimura L C, Lo P, Ford R J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88–95
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007; 109: 4441–4449
   PubMed Web of Science ®Google Scholar
• Fernandez Y, Verhaegen M, Miller T P, Rush J L, Steiner P, Opipari A W, Jr., et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005; 65: 6294–6304
   PubMed Web of Science ®Google Scholar
• Qin J Z, Ziffra J, Stennett L, Bodner B, Bonish B K, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282–6293
   PubMed Web of Science ®Google Scholar
• Iglesias-Serret D, de F M, Santidrian A F, Coll-Mulet L, Cosialls A M, Barragan M, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007; 21: 281–287
   PubMed Web of Science ®Google Scholar
• Puthalakath H, O'Reilly L A, Gunn P, Lee L, Kelly P N, Huntington N D, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007; 129: 1337–1349
   PubMed Web of Science ®Google Scholar
• Concannon C G, Koehler B F, Reimertz C, Murphy B M, Bonner C, Thurow N, et al. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene 2007; 26: 1681–1692
   PubMed Web of Science ®Google Scholar
• Mestre-Escorihuela C, Rubio-Moscardo F, Richter J A, Siebert R, Climent J, Fresquet V, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271–280
   PubMed Web of Science ®Google Scholar
• Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348–1358
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella V J, Sausville E A, Johnson J, Destree A, Lazarus D D, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
   PubMed Web of Science ®Google Scholar
• Renard P, Ernest I, Houbion A, Art M, Le C H, Raes M, Remacle J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 2001; 29: E21
   PubMedGoogle Scholar
• Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson K C. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003; 63: 6174–6177
   PubMed Web of Science ®Google Scholar
• Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai Y T, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145–156
   Google Scholar
• Snowden R T, Sun X M, Dyer M J, Cohen G M. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 2003; 17: 1981–1989
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297–309
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R A. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers C L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Tapia M A, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006; 5: 665–675
   PubMed Web of Science ®Google Scholar
• David E, Sun S Y, Waller E K, Chen J, Khuri F R, Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005; 106: 4322–4329
   PubMed Web of Science ®Google Scholar
• Shi Y Y, Small G W, Orlowski R Z. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006; 100: 33–47
   Google Scholar
• Voorhees P M, Orlowski R Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46: 189–213
   PubMed Web of Science ®Google Scholar
• Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65: 5599–5606
   PubMed Web of Science ®Google Scholar
• Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991; 51: 6677–6685
   PubMed Web of Science ®Google Scholar
• Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset J M, Dumont J, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105: 752–757
   PubMed Web of Science ®Google Scholar
• Strauss S J, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007; 67: 2783–2790
   PubMed Web of Science ®Google Scholar
• Willis S N, Chen L, Dewson G, Wei A, Naik E, Fletcher J I, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294–1305
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993–4999
   PubMed Web of Science ®Google Scholar
• Chen L, Willis S N, Wei A, Smith B J, Fletcher J I, Hinds M G, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403
   PubMed Web of Science ®Google Scholar
• Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005; 280: 10491–10500
   PubMed Web of Science ®Google Scholar
• Nikiforov M A, Riblett M, Tang W H, Gratchouck V, Zhuang D, Fernandez Y, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci USA 2007; 104: 19488–19493
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Richardson P G, Poulaki V, Tai Y T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
   PubMed Web of Science ®Google Scholar